Bipolar Medication Options: What to Expect and How to Choose

Bipolar disorder is managed with four main medication classes: mood stabilizers (lithium), anticonvulsants used as mood stabilizers (valproic acid/divalproex, lamotrigine, carbamazepine), atypical antipsychotics (quetiapine, olanzapine, lurasidone, aripiprazole, risperidone, lumateperone), and selected antidepressants used as adjuncts (fluoxetine, most often in the olanzapine-fluoxetine combination). Each class targets a different phase of illness. Antipsychotics and valproate work fastest for acute mania. Quetiapine, lurasidone, olanzapine-fluoxetine (Symbyax), and lumateperone address bipolar depression. Lithium carries the strongest long-term evidence for relapse prevention across both poles.

The medications covered in this article include:

• Lithium (mood stabilizer, maintenance and mania)
• Valproic acid / Divalproex (Depakote) (anticonvulsant/mood stabilizer, mania and maintenance)
• Lamotrigine (Lamictal) (anticonvulsant, depressive relapse prevention)
• Carbamazepine (anticonvulsant, mania and mixed states)
• Quetiapine (Seroquel) (atypical antipsychotic, mania, bipolar depression, maintenance)
• Olanzapine (Zyprexa) (atypical antipsychotic, mania and maintenance)
• Olanzapine + Fluoxetine (Symbyax) (combination, bipolar depression)
• Lurasidone (Latuda) (atypical antipsychotic, bipolar depression)
• Aripiprazole (Abilify) (atypical antipsychotic, mania and maintenance)
• Risperidone (Risperdal) (atypical antipsychotic, acute mania)
• Lumateperone (Caplyta) (atypical antipsychotic, bipolar depression)
• Fluoxetine (Prozac) (antidepressant, adjunct only, not monotherapy in bipolar I)

Seek emergency care immediately if you or someone you care for is experiencing dangerous or uncontrollable manic behavior, suicidal thoughts, signs of severe allergic reaction (throat swelling, difficulty breathing), or sudden confusion with a high fever. These are not situations to manage at home while waiting for a scheduled appointment.

Key Takeaways

Lithium remains the most evidence-supported long-term option for bipolar disorder, but the right medication depends on your phase of illness, medical history, and individual response, making shared decision-making with a psychiatrist the essential first step.

This article is for general informational purposes only and is not a substitute for professional medical advice. Always consult a qualified psychiatrist or healthcare provider before starting, changing, or stopping any medication for bipolar disorder.

Table of Contents

• What are the main bipolar medication options and how do they work?
• Which medications are used for mania, bipolar depression, and maintenance?
• How do clinicians choose medications, and what should you expect from monitoring?
• What side effects and long-term safety concerns should you know about?
• FDA-approved medications for bipolar disorder: a quick reference
• Why medication alone is usually not enough
• What do current guidelines and research say about effectiveness?
• An honest perspective on choosing bipolar medications
• Medication management and psychiatric care at Imindmental
• Sources

What are the main bipolar medication options and how do they work?

Understanding how each medication class works makes it easier to have an informed conversation with your prescriber. The Merck Manual’s clinical reference groups bipolar medications into lithium, anticonvulsants, and atypical antipsychotics as the core options, with antidepressants and adjuncts playing supporting roles.

Mood stabilizers: lithium

Lithium is the original mood stabilizer and still the most studied drug for long-term bipolar management. It works by modulating intracellular signaling pathways, though the precise mechanism continues to be studied. Its main advantages are a strong evidence base for relapse prevention and a well-documented reduction in suicide risk. The trade-off is a narrow therapeutic window: too little and it does not work; too much and it becomes toxic. Regular blood-level monitoring is non-negotiable.

Anticonvulsants used as mood stabilizers

• Valproic acid / Divalproex (Depakote): Broadly effective for acute mania and mixed states. Faster to titrate than lithium in some settings. Significant concerns include weight gain, liver toxicity, and a serious teratogenicity risk that makes it contraindicated in pregnancy and in girls and women of childbearing potential.
• Lamotrigine (Lamictal): Particularly useful for preventing depressive relapse. Onset is slow because the dose must be increased gradually to reduce the risk of a serious rash (Stevens-Johnson syndrome). Less effective for acute mania.
• Carbamazepine: An option for mania and mixed states, especially when lithium has not worked. Requires CBC and liver monitoring due to blood dyscrasia risk. Also a strong inducer of liver enzymes, which complicates polypharmacy.

Atypical antipsychotics

This class has expanded significantly in bipolar treatment over the past two decades. Quetiapine (Seroquel), olanzapine (Zyprexa), aripiprazole (Abilify), risperidone (Risperdal), lurasidone (Latuda), and lumateperone (Caplyta) all have FDA approvals for one or more phases of bipolar disorder. Their shared mechanism involves dopamine and serotonin receptor modulation. The class-wide concern is metabolic risk: weight gain, elevated blood sugar, and lipid changes are common, particularly with olanzapine and quetiapine.

Antidepressants as adjuncts

Fluoxetine (Prozac) is the most studied antidepressant in bipolar disorder, primarily through its combination with olanzapine (Symbyax), which carries an FDA approval for bipolar depression. Antidepressants are not used as monotherapy in bipolar I because of the risk of triggering a manic switch. When used at all, they are paired with a mood stabilizer or antipsychotic under close supervision.

Adjunctive medications

Benzodiazepines (such as lorazepam or clonazepam) are sometimes used short-term during acute mania for sedation and agitation control. They are not mood stabilizers and are not used for maintenance.

Pro Tip: Your prescriber’s first question is usually “what has worked or failed before?” Prior response history, including a family member’s response to a specific drug, often predicts your own response better than any general guideline. If you have that information, bring it to your first appointment.

Which medications are used for mania, bipolar depression, and maintenance?

The phase of illness matters enormously when choosing among bipolar disorder drugs. A drug that works well for acute mania may do little for depressive episodes, and a drug that prevents depressive relapse may not be the right choice during a manic crisis.

First-line options by phase

Acute mania:
Atypical antipsychotics are generally the fastest-acting options and have strong evidence from meta-analyses and systematic reviews. Quetiapine, olanzapine, aripiprazole, and risperidone are all used. Valproate and lithium are also first-line, though lithium typically takes longer to reach therapeutic levels. Carbamazepine is a second-line option for mania that has not responded to first-line agents.

Bipolar depression:
Quetiapine has the broadest evidence base and regulatory approval for bipolar depression. Lurasidone (Latuda) and the olanzapine-fluoxetine combination (Symbyax) also carry FDA approvals for this indication. Lumateperone (Caplyta) has more recently received approval for bipolar depression. Lamotrigine is widely used for depressive relapse prevention, though its evidence for acute bipolar depression is more limited.

Maintenance (relapse prevention):
Lithium has the strongest randomized-trial evidence for long-term relapse prevention of any agent in bipolar disorder. Lamotrigine is particularly effective at preventing depressive relapses, with pooled trial data showing a 36% reduction in relapse risk for depressive episodes over 18 months. Valproate is widely used for maintenance, though its placebo-controlled long-term evidence is less robust than lithium’s. Quetiapine and aripiprazole also have maintenance approvals.

A note on antidepressants:
Fluoxetine and other antidepressants should not be used as monotherapy in bipolar I. Current clinical practice guidelines warn that unopposed antidepressant use carries a real risk of triggering a manic or hypomanic switch. When an antidepressant is considered, it is added to an established mood stabilizer or antipsychotic, and the decision requires close clinical judgment.

For severe or treatment-resistant cases:
When multiple medication trials have not produced adequate response, combination strategies (such as lithium plus valproate, or adding an antipsychotic to a mood stabilizer) are the next step. Electroconvulsive therapy (ECT) remains an option for severe, refractory illness and for acute suicidal crises. Brain stimulation therapies including TMS are also considered in certain treatment-resistant presentations.

How do clinicians choose medications, and what should you expect from monitoring?

Choosing among medications for bipolar disorder is rarely straightforward. The Merck Manual is clear that individualized selection based on medical history, comorbidities, and prior response is the standard of care, not a one-size-fits-all protocol.

Clinical factors that shape the decision

• Prior response: The single strongest predictor of how you will respond to a drug is how you or a close biological relative responded to it before.
• Pregnancy plans: Valproate is contraindicated for girls and women of childbearing potential. Lithium carries neonatal risks and requires careful planning. Lamotrigine is relatively safer but dose adjustments during pregnancy are needed.
• Renal and thyroid status: Lithium is cleared by the kidneys and affects thyroid function. Existing kidney disease or thyroid conditions may steer the decision toward a different agent.
• Liver status: Valproate and carbamazepine both carry hepatotoxicity risk. Liver disease or elevated baseline liver enzymes are important factors.
• Rapid cycling or mixed states: Valproate and atypical antipsychotics tend to be preferred over lithium alone in rapid-cycling presentations.
• Comorbid conditions: Anxiety, substance use, metabolic syndrome, and cardiovascular disease all influence which agents are safest and most practical.
• Tolerability history: Weight gain, sedation, cognitive effects, and sexual side effects are among the most common reasons people stop taking medications. Discussing these upfront helps set realistic expectations.

Questions to ask your prescriber

1. What is the target outcome for this medication, and how will we know it is working?
2. How long before I can expect to notice a meaningful effect?
3. What labs do I need before starting, and how often will they be repeated?
4. What side effects are most likely, and what should I do if they occur?
5. Are there interactions with other medications, supplements, or alcohol I should know about?
6. What is the plan if this medication does not work well enough?
7. If I am or plan to become pregnant, how does that change the options?

Pharmacogenomic testing is an emerging tool that can inform medication selection by identifying genetic variants that affect how your body metabolizes specific drugs. It does not replace clinical judgment, but it can reduce trial-and-error in some cases.

Monitoring schedule: what to expect

Lithium:

• Baseline: serum creatinine, thyroid-stimulating hormone (TSH), complete blood count (CBC), urinalysis, and a pregnancy test if applicable.
• Serum lithium levels checked 5–7 days after each dose change, then every 3–6 months once stable. Typical maintenance target is approximately 0.6–1.0 mEq/L, though targets vary by age and clinical situation.
• Renal function and TSH every 6–12 months.

Valproate / Divalproex:

• Baseline liver enzymes, CBC, and platelets before starting.
• Serum valproate levels, liver enzymes, and platelets at 1 month, then every 6–12 months.

Carbamazepine:

• Baseline CBC and liver enzymes.
• CBC and liver enzymes at 2 weeks, 1 month, then every 3–6 months.

Atypical antipsychotics:

• Baseline weight, waist circumference, fasting glucose, and fasting lipid panel.
• Weight at every visit for the first 3 months, then quarterly.
• Fasting glucose and lipids at 3 months, then annually.

What to expect in the first 6–12 weeks

1. Week 1–2: Dose is started low. Mild side effects (sedation, nausea, mild tremor) are common and often improve.
2. Week 2–4: First dose adjustment based on tolerability and initial response. First lab check for lithium or valproate.
3. Week 4–6: Clearer picture of whether the medication is helping. Mood tracking is useful here.
4. Week 6–12: If response is partial, dose may be optimized or an adjunctive agent considered.
5. After 12 weeks: If there is no meaningful response, a medication switch or combination strategy is discussed.

Red flags requiring urgent contact

• Suicidal thoughts or plans
• Signs of lithium toxicity: coarse tremor, confusion, vomiting, unsteady gait
• Skin rash, especially with lamotrigine (could indicate Stevens-Johnson syndrome)
• Fever with sore throat and mouth sores (possible agranulocytosis with carbamazepine)
• Severe abdominal pain (possible pancreatitis with valproate)
• Yellowing of skin or eyes (possible liver injury with valproate or carbamazepine)

What side effects and long-term safety concerns should you know about?

Every medication in this group carries a side-effect profile worth understanding before you start. The goal is not to alarm you but to help you recognize what is expected, what to monitor, and when to call your prescriber.

Class-by-class side effects

• Lithium: Tremor, increased thirst and urination, weight gain, and cognitive dulling are the most common. Long-term use is associated with hypothyroidism and, in some patients, gradual decline in kidney function. Regular renal and thyroid monitoring is standard practice.
• Valproate / Divalproex: Weight gain, hair thinning, sedation, and gastrointestinal upset are frequent. Serious but less common risks include hepatotoxicity and pancreatitis. The teratogenicity risk is severe: the WHO explicitly warns that valproate should be avoided in girls and women of childbearing potential.
• Lamotrigine: Generally well tolerated. The primary safety concern is a serious skin rash, including Stevens-Johnson syndrome, which is why the dose must be increased slowly over several weeks. Headache and dizziness are the most common mild side effects.
• Carbamazepine: Dizziness, diplopia (double vision), and sedation are common early on. Blood dyscrasias (including rare but serious agranulocytosis) and liver enzyme elevation require regular CBC and liver monitoring.
• Atypical antipsychotics (quetiapine, olanzapine, aripiprazole, risperidone, lurasidone, lumateperone): Weight gain and metabolic syndrome are the most clinically significant long-term concerns, particularly with olanzapine and quetiapine. Sedation is common, especially with quetiapine. Risperidone and lurasidone can elevate prolactin. Aripiprazole and lurasidone tend to have a more favorable metabolic profile within this class.

On lithium and suicide risk: Meta-analyses of randomized maintenance trials have found that lithium is associated with a meaningful reduction in suicidal behavior compared to placebo or other comparators. This is one of the few areas in psychiatry where a specific drug has this level of evidence for suicide prevention, and it is a clinically important consideration when weighing treatment options.

Managing side effects in practice

Weight gain from antipsychotics is one of the most common reasons people stop taking their medication. Structured lifestyle support, dietary guidance, and regular metabolic monitoring are part of responsible prescribing. In some cases, a clinician may discuss adjunctive strategies to address metabolic changes; this is a conversation to have with your prescriber rather than a self-managed decision.

Drug interactions are a real concern with this medication class. Carbamazepine is a potent inducer of liver enzymes and can reduce the effectiveness of many other medications, including oral contraceptives. Lithium levels can be affected by NSAIDs (like ibuprofen), diuretics, and ACE inhibitors. Alcohol amplifies sedation with most of these agents and can destabilize mood. Always give your prescriber a complete list of everything you take, including supplements and over-the-counter medications.

Medication optimization is an ongoing process, not a one-time decision. Side effects that are unmanageable at one dose may be tolerable at a lower dose combined with a second agent.

FDA-approved medications for bipolar disorder: a quick reference

The table below reflects FDA-approved indications for the medications covered in this article, based on the NCBI FDA-approved medications reference. Approvals are specific to the indication listed; use in other phases may be clinically common but off-label.

A note on off-label use: Several agents in this table are commonly used in phases for which they do not hold a specific FDA approval. Off-label prescribing is legal and clinically standard when supported by evidence and clinical judgment. Your prescriber can explain the evidence base for any off-label recommendation they make.

Monitoring requirements vary by agent. Lithium requires regular serum level checks and renal/thyroid surveillance. Valproate and carbamazepine require liver enzyme and blood count monitoring. Atypical antipsychotics require metabolic screening. These are not optional add-ons; they are part of safe prescribing for this medication class.

Why medication alone is usually not enough

Medication stabilizes mood episodes and reduces relapse risk. But the evidence consistently shows that medication combined with psychosocial treatment produces better long-term outcomes than medication alone. Clinical practice guidelines recommend combining pharmacotherapy with psychosocial interventions as the standard of care, not an optional enhancement.

The psychosocial approaches with the strongest evidence include:

• Cognitive behavioral therapy (CBT): Helps identify and interrupt thought patterns that precede mood episodes, and builds coping strategies for managing early warning signs.
• Psychoeducation: Teaching patients and families about the illness, its phases, and the role of medication significantly improves medication adherence and reduces hospitalization rates.
• Family-focused therapy: Particularly useful when family dynamics contribute to stress that triggers episodes. Involves family members directly in the treatment plan.
• Interpersonal and social rhythm therapy (IPSRT): Targets the disruption of daily routines and sleep-wake cycles that often precede mood episodes. Sleep and circadian rhythm stability are among the most reliable protective factors in bipolar disorder.
• Adherence-focused therapy: Addresses the ambivalence many people feel about long-term medication use, especially during periods of stability when the illness feels distant.

The WHO frames this clearly: medicines are essential but typically insufficient on their own. Combined treatment planning is the goal, not a fallback for people who do not respond to medication.

Pro Tip: Start psychoeducation as early as possible in treatment, ideally before or alongside the first medication trial. Patients who understand their illness and its warning signs are more likely to stay on medication during stable periods, which is when adherence tends to slip.

What do current guidelines and research say about effectiveness?

The evidence base for bipolar medications is more nuanced than most medication guides suggest. Here is what the major reviews and guidelines actually say.

What the guidelines agree on

• Medication combined with psychosocial care is the standard of care. Neither alone is as effective as both together.
• Lithium has the strongest randomized evidence for long-term relapse prevention of any single agent. It is also the only drug with randomized evidence for reducing suicidal behavior.
• Atypical antipsychotics are effective for acute mania, with quetiapine and the olanzapine-fluoxetine combination having the clearest evidence for bipolar depression.
• Valproate is not recommended for use in pregnancy or in girls and women of childbearing potential.
• Antidepressant monotherapy in bipolar I is not recommended due to switch risk.

Where the evidence is less settled

The picture gets more complicated for long-term outcomes. Systematic reviews note that most advances in recent years have been refinements in antipsychotic use and combination strategies rather than genuinely new drug classes. Long-term disease-modifying evidence for many agents remains limited, and the field continues to debate the role of antidepressants in bipolar depression.

Valproate is widely used for maintenance despite relatively sparse placebo-controlled long-term trial data compared to lithium. Carbamazepine has a similar evidence gap for maintenance. This does not mean these drugs do not work for maintenance; it means the evidence base is thinner than the clinical use might suggest.

On the antidepressant controversy: The use of antidepressants in bipolar depression remains one of the most debated areas in psychiatry. Current guidelines caution against their use as monotherapy in bipolar I and recommend close monitoring for mood switching when they are used adjunctively. For some patients with bipolar II or a predominantly depressive course, the calculus may differ, but this is a decision that requires careful, individualized clinical judgment.

What this means for your treatment plan

No single medication works for everyone. Finding the right regimen commonly requires careful titration and close follow-up, particularly in the first weeks of a new medication trial. Current guidelines support combination therapy and, in severe or refractory cases, ECT or other neurostimulation approaches as legitimate next steps when pharmacotherapy alone is insufficient.

An honest perspective on choosing bipolar medications

There is a tendency in patient-facing medication guides to present bipolar treatment as a clean decision tree: try this first, then that, then the other. The reality is messier, and pretending otherwise does patients a disservice.

The most important thing most guides underemphasize is this: the medication that works for you is not necessarily the one with the best population-level evidence. Lithium has the strongest long-term data, but a patient with significant kidney disease, or one who cannot tolerate the monitoring burden, may do better on a different regimen. Lamotrigine has a favorable side-effect profile, but its slow titration schedule means it is not the right choice when someone is in acute crisis.

Shared decision-making is not a formality. It is the mechanism by which a clinician’s knowledge of the evidence gets matched to your specific medical history, your life circumstances, and your own priorities. A prescriber who does not ask about your pregnancy plans, your kidney function, your prior medication history, and your tolerance for weight gain is not doing shared decision-making. You deserve that conversation.

The other underappreciated reality is that medication management for bipolar disorder is a long-term relationship, not a one-time prescription. Doses change. Life stages change. What worked at 30 may need adjustment at 55. Adolescents and older adults both require modified approaches because of differences in metabolism, comorbidities, and drug sensitivity. Staying connected to a prescriber who knows your history is one of the most protective things you can do.

Medication management and psychiatric care at Imindmental

Managing bipolar disorder medications well requires more than a prescription. It requires consistent follow-up, lab monitoring, and a prescriber who knows your full history. Imindmental offers psychiatry and medication management services in Port St. Lucie, Vero Beach, and Stuart, FL, as well as via telehealth for patients across Florida.

At your initial evaluation, your clinician will review your full medication history, current symptoms, and any relevant lab work. Follow-up visits are scheduled to align with monitoring requirements: lithium levels, metabolic panels for antipsychotics, and liver checks for anticonvulsants are built into the care plan, not left to chance. For patients whose depressive symptoms have not responded to medication alone, Imindmental also offers TMS therapy and Spravato (esketamine) treatment as evidence-based options.

To get started, visit Imindmental’s services page to learn what to expect from a psychiatric evaluation, or go directly to Imindmental to book an appointment or verify your insurance.

Sources

The following sources were used to support the clinical claims in this article:

• Treatment of bipolar disorder – PMC
• Bipolar disorder – WHO fact sheet
• Medications for Treatment of Bipolar Disorders – Merck Manual Professional Edition
• Table 1, FDA-approved medications for bipolar disorder – NCBI

Recommended

• Bipolar Disorder Explained: Symptoms, Causes & Treatment
• When Depression Medication Is Not Working: Next Steps
• Benefits of Medication Management for Depression
• Top Brain Stimulation Therapies Compared: Which Fits You?